Tyra Biosciences' TYRA-300, an oral FGFR3 inhibitor, showed promising efficacy but raised concerns with some FGFR1/2-driven adverse events, causing a significant stock drop. TYRA-300 demonstrated ...

and the inhibition of this pathway by a FGFR1 inhibitor reversed KLX's effects. These findings highlight the role of KLX in modulating key signaling pathways involved in EndMT and atherosclerosis ...

and the inhibition of this pathway by a FGFR1 inhibitor reversed KLX's effects. These findings highlight the role of KLX in modulating key signaling pathways involved in EndMT and atherosclerosis ...